The Pharmacy Times® Dermatology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of skin disorders, including psoriasis, atopic dermatitis, eczema, and acne.
November 5th 2024
About 41% and 30% of patients with chronic spontaneous urticaria (CSU), respectively, achieved well-controlled disease status and complete response when treated with dupilumab.
Best Practices for Optimizing Biologic Therapy Management for Moderate to Severe Atopic Dermatitis in Children
1.5 Credits / Dermatology, Immunology
View More
The Evolving Treatment Paradigm of Demodex Blepharitis: Considerations for Pharmacists (Pharmacy Technician Cr...
1.0 Credits / Ophthalmology/Optometry, Dermatology
View More
The Evolving Treatment Paradigm of Demodex Blepharitis: Considerations for Pharmacists (Pharmacist Credit)
1.0 Credits / Ophthalmology/Optometry, Dermatology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Navigating the Complexities of Biologic Therapy for Moderate to Severe Atopic Dermatitis in Children: The Impa...
1.5 Credit / Dermatology, Immunology
View More
The Role of Daily Photoprotection and Antioxidants in Sun Protection: A Guide for Pharmacists and Pharmacy Tec...
1.0 Credit / Dermatology, OTC
View More
Adjunctive Therapies in Atopic Dermatitis: Understanding the Role of the Skin Barrier and Microbiome in Diseas...
1.0 Credit / Dermatology, OTC
View More
Skin-Related Changes in Persons With Diabetes: Using Ceramides to Address Skin Barrier Dysfunction (Pharmacy T...
1.0 Credit / Dermatology, OTC
View More
Understanding the Role of Ceramides in Acne Management: Opportunities to Improve Clinical Outcomes (Pharmacy T...
1.0 Credit / Dermatology, OTC
View More
Alleviating Patient Burden in Acne: Utilizing Ceramides to Address Skin Barrier Dysfunction (Pharmacy Technici...
0.75 Credit / Dermatology, OTC
View More
Examining Patient Burden in Atopic Dermatitis: Understanding Treatment Barriers and Optimal Use of OTC Skin Ca...
0.5 Credit / Dermatology, OTC
View More
Addressing the Challenges of Treating Moderate to Severe Atopic Dermatitis With Targeted Biologic Therapies in...
1.5 Credits / Allergy, Dermatology, Immunology
View More
Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care
1.5 Credits / Dermatology, Immunology
View More
Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care
1.5 Credits / Dermatology
View More
Alleviating Patient Burden in Acne: Utilizing Ceramides to Address Skin Barrier Dysfunction
0.75 Credit / Dermatology, OTC
View More
Examining Patient Burden in Atopic Dermatitis: Understanding Treatment Barriers and Optimal Use of OTC Skin Ca...
0.5 Credit / Dermatology, OTC
View More
Skin-Related Changes in Persons With Diabetes: Using Ceramides to Address Skin Barrier Dysfunction
1.0 Credit / Dermatology, OTC
View More
Adjunctive Therapies in Atopic Dermatitis: Understanding the Role of the Skin Barrier and Microbiome in Diseas...
1.0 Credit / Dermatology, OTC
View More
Understanding the Role of Ceramides in Acne Management: Opportunities to Improve Clinical Outcomes
1.0 Credit / Dermatology, OTC
View More
The Role of Daily Photoprotection and Antioxidants in Sun Protection: A Guide for Pharmacists and Pharmacy Tec...
1.0 Credit / Dermatology, OTC
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
June 11th 2024At the ASHP Pharmacy Futures 2024 conference, Scott D. Nelson, PharmD, MS, ACHIP, FAMIA, discusses research showed that although AI models can significantly enhance diagnostic accuracy, they can also exacerbate existing disparities.
Read More
FDA Accepts Supplemental New Drug Application for Tapinarof Cream, 1%, in Atopic Dermatitis
April 29th 2024The acceptance is based on positive data from the phase 3 ADORING 1 and ADORING 2 pivotal trials, as well as interim results from the phase 3 ADORING 3 open-label, long-term extension trial.
Read More